

December 29, 2009

SUBJECT: Fibromyalgia & Antimigraine Step Therapy

The step therapy requirements listed below will take effect January 11, 2010.

Approval Criteria:

- 1. Recent trials (within the last six months) of two Tier-1 medications at least 3 weeks in duration that did not provide adequate response, or resulted in intolerable adverse effects, or
- 2. Contraindication(s) to all available lower tiered medications,
- 3. Current stabilization on a Tier 2 medication (Samples will not be accepted if member has not had appropriate lower tiered trials.)

Tier 1	Tier 2
Amitriptyline	Pregabalin (Lyrica®)
Cyclobenzaprine	Duloxetine HCl (Cymbalta®)
Fluoxetine Tramadol	Milnacipran (Savella™)
Tamado	

Antimigraine Step Therapy

Tier 2 Approval Criteria:

- Trial of all available Tier 1 products with inadequate response, or
- Documented adverse effect to all the Tier 1 products, or
- Previous success with a Tier 2 product within the last 60 days.

Tier 3 Approval Criteria:

- Trial of all available Tier 2 products with inadequate response, or
- Documented adverse effect to all available Tier 2 products, or
- Previous success with a Tier 3 medication within the last 60 days.

Tier 2	Tier 3
Naratriptan (Amerge®)	Almotriptan (Axert®)
Sumatriptan/Naproxen (Treximet®)	Eletriptan (Relpax®)
	Frovatriptan (Frova®)
	Rizatriptan (Maxalt®; Maxalt MLT®)
	Zolmitriptan (Zomig®; Zomig-ZMT®)
	Naratriptan (Amerge®)

Email: pharmacy@okhca.org OHCA Website: www.okhca.org/providers/rx/pa PA forms: www.okhca.org/rx-forms